Navigation Links
Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
Date:6/8/2009

n via a single insertion of ITCA 650.

    Fasting & Postprandial Glucose             ITCA 650 Dose Arms
                                             (continuous daily dose)
                                       10        20        40        80
                                     mcg/day   mcg/day   mcg/day   mcg/day
    Mean FPG at baseline (mg/dL)      161.2     170.5     171.8     145.1
    Mean FPG at end of treatment
     (mg/dL)                          155.6     139.4     129.8     116.3
    Change from baseline (mg/dL)       -5.6     -31.1     -42.0     -28.8
    Change in 2-hr PPG at end of
     treatment (mg/dL)                 -8.8     -32.3     -47.1     -74.6


Substantial decreases in FPG and PPG were observed throughout treatment. Decreases in FPG were evident within 24 hours of the initiation of treatment suggesting a rapid and consistent achievement of desired exenatide levels with DUROS delivery. Changes in PPG measured at days 15 and 29 also showed consistent dose-dependent reductions.

    HbA1c & Body Weight                        ITCA 650 Dose Arms
                                             (continuous daily dose)
                                       10        20        40        80
                                     mcg/day   mcg/day   mcg/day   mcg/day
    % HbA1c at baseline               7.67      7.90      7.45      7.38
    % HbA1c at end of treatment       7.15      7.28      7.00      6.80
    Change from baseline             -0.52     -0.62     -0.45     -0.58
    Mean change in weight (kg)       -0.28     -0.31     -0.93     -2.91

Although the treatment duration in the study was only 28 days, decreases in HbA1c and body weight were observed across all dose arms. The most commonly reported adverse events were nausea and vomiting which were mostly mild, transient and dose dependent.

"The results
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
2. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
3. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
4. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
5. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
6. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
7. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
9. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
10. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
11. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Local veterinarian, Dr. Keith ... are seeking candidates to participate in an investigational study ... The ultimate goal of this study is to determine ... one or two arthritically affected joints can help reduce ... Candidates for the current investigational study must be older ...
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 “This kit ... test to screen from 0 to 150 ppb,” said Mark ... is a significant benefit to plant owners and USDA-GIPSA inspection ... and other commodities. Testing can take place in a matter ... only can the plant test the feed and grain before ...
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... diaDexus, Inc. (OTC Bulletin Board: DDXS ... commercialization of patent-protected in vitro diagnostic products ... the company, formerly known as VaxGen, Inc. and traded ... (VXGN), has been renamed diaDexus, Inc. diaDexus, common stock ...
... and latest developments ... ... --> ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:diaDexus Announces Name Change From VaxGen 2diaDexus Announces Name Change From VaxGen 3NEURO-BIOTECH CORPORATION: Updates and latest developments 2NEURO-BIOTECH CORPORATION: Updates and latest developments 3NEURO-BIOTECH CORPORATION: Updates and latest developments 4NEURO-BIOTECH CORPORATION: Updates and latest developments 5NEURO-BIOTECH CORPORATION: Updates and latest developments 6NEURO-BIOTECH CORPORATION: Updates and latest developments 7NEURO-BIOTECH CORPORATION: Updates and latest developments 8NEURO-BIOTECH CORPORATION: Updates and latest developments 9Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 2Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 3Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 4Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 5Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 6Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 7Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 8
(Date:8/29/2014)... is available in German . ... in the natural nitrogen cycle on Earth and in ... were thought to depend on nitrite as their source ... Holger Daims, a microbiologist at the University of Vienna, ... as an alternative source of energy. The oxidation of ...
(Date:8/29/2014)... - The rise of the Tibetan plateau -- the ... is important for both its profound effect on climate ... published in GSA Bulletin , Katharine Huntington and ... thermometry -- using modern and fossil snail shells to ... southwestern Tibet. , Views range widely on the ...
(Date:8/28/2014)... available in German . ... its name to a striking pattern of blue stripes alternating ... reflective silvery cells, and yellow cells emerge during growth in ... a multilayered mosaic to compose the characteristic colour pattern. ... have to interact to form proper stripes, the embryonic origin ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... the Robarts Research Institute at The University of Western ... used a unique genetically-modified mouse line to reveal a ... led by Marco Prado, Robert Gros and Vania Prado ... how the decreased release of the neurotransmitter acetylcholine, a ...
... Cancer Institute have further developed a potential new treatment ... cancer cells, removing them from the body. The treatment, ... using samples from human cancer patients. The results appear ... are primarily interested in developing an effective method to ...
... (Boston) Boston University School of Medicine (BUSM) ... physiology, with joint appointments in biomedical engineering and medicine, ... Lipids. This award is being bestowed by ... in the application of nuclear magnetic resonance methods to ...
Cached Biology News:Genetically-modified mice reveal another mechanism contributing to heart failure 2Magnetic nanoparticles show promise for combating human cancer 2
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
... Antibody to CRF The ... ovine CRF sequence that it ... fibres are found in the ... brain in colchicine treated 4% ...
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Biology Products: